肠道微生物组分析作为早期肝细胞癌靶向无创生物标志物的工具
该研究前瞻性收集中国华东、华中、西北地区486份粪便样本,最终419份完成Miseq测序,在75例早期肝细胞癌、40例肝硬化和75例健康对照中构建并验证肠道微生物组肝细胞癌分类器,并在新疆和郑州的肝细胞癌样本中进行跨区域验证。
要点
- 早期肝细胞癌与肝硬化相比,放线菌门及包括Gemmiger和Parabacteroides在内的13个菌属增多。
- 30个微生物标志物在75例早期肝细胞癌与105例非肝细胞癌样本间构建的分类器曲线下面积为80.64%。
- 微生物标志物在西北地区和华中地区肝细胞癌样本中实现跨区域验证。
核心结论
- 本研究首次描述肝细胞癌患者肠道微生物组特征,并报告成功建立肝细胞癌诊断模型及微生物标志物的跨区域验证,肠道微生物靶向标志物是早期肝细胞癌诊断的潜在无创工具。
研究设计与样本
- 前瞻性收集中国华东、华中、西北地区486份粪便样本,最终419份完成Miseq测序;在75例早期肝细胞癌、40例肝硬化、75例健康对照中构建分类器,并在56例对照、30例早期肝细胞癌、45例晚期肝细胞癌中验证,另在新疆18例和郑州80例肝细胞癌中进一步验证诊断潜力。
主要发现
- 粪便微生物多样性从肝硬化到合并肝硬化的早期肝细胞癌增加;早期肝细胞癌较肝硬化放线菌门增多,包括Gemmiger和Parabacteroides在内的13个菌属富集;早期肝细胞癌较对照产丁酸菌属减少、产脂多糖菌属增多。
- 通过随机森林模型五折交叉验证识别出最优30个微生物标志物,在75例早期肝细胞癌与105例非肝细胞癌样本间曲线下面积为80.64%。
- 肠道微生物标志物对早期肝细胞癌乃至晚期肝细胞癌均显示出较强诊断潜力,并在西北地区和华中地区肝细胞癌样本中成功实现跨区域验证。
关键数值与推荐
- 30个微生物标志物在75例早期肝细胞癌与105例非肝细胞癌样本间曲线下面积为80.64%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterise gut microbiome in patients with hepatocellular carcinoma (HCC) and evaluate the potential of microbiome as non-invasive biomarkers for HCC. DESIGN: We collected 486 faecal samples from East China, Central China and Northwest China prospectively and finally 419 samples completed Miseq sequencing. We characterised gut microbiome, identified microbial markers and constructed HCC classifier in 75 early HCC, 40 cirrhosis and 75 healthy controls. We validated the results in 56 controls, 30 early HCC and 45 advanced HCC. We further verified diagnosis potential in 18 HCC from Xinjiang and 80 HCC from Zhengzhou. RESULTS: Faecal microbial diversity was increased from cirrhosis to early HCC with cirrhosis. Phylum Actinobacteria was increased in early HCC versus cirrhosis. Correspondingly, 13 genera including Gemmiger and Parabacteroides were enriched in early HCC versus cirrhosis. Butyrate-producing genera were decreased, while genera producing-lipopolysaccharide were increased in early HCC versus controls. The optimal 30 microbial markers were identified through a fivefold cross-validation on a random forest model and achieved an area under the curve of 80.64% between 75 early HCC and 105 non-HCC samples. Notably, gut microbial markers validated strong diagnosis potential for early HCC and even advanced HCC. Importantly, microbial markers successfully achieved a cross-region validation of HCC from Northwest China and Central China. CONCLUSIONS: This study is the first to characterise gut microbiome in patients with HCC and to report the successful diagnosis model establishment and cross-region validation of microbial markers for HCC. Gut microbiota-targeted biomarkers represent potential non-invasive tools for early diagnosis of HCC.
引用
- Ren Z, Li A, Jiang J, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut. 2018. PMID: 30045880. doi:10.1136/gutjnl-2017-315084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。